Chorioamnionitis medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(2 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Chorioamnionitis}}
{{Chorioamnionitis}}
{{CMG}}
{{CMG}} ; {{AE}} {{Adnan Ezici}}
=Overview=
=Overview=
Antimicrobial therapy is indicated among patients with chorioamnionitis.  The preferred regimen is a combination of [[ampicillin]] and [[gentamicin]].  Supportive therapy, such as antipyretics, may also be used.
Antimicrobial therapy is indicated among patients with chorioamnionitis.  The preferred regimen is a combination of [[ampicillin]] and [[gentamicin]].  Supportive therapy, such as antipyretics, may also be used.
==Medical Therapy==
==Medical Therapy==
Medical therapy for chorioamnionitis includes antimicrobial therapy and antipyretic therapy:
Medical therapy for chorioamnionitis includes antimicrobial therapy and supportive therapy:
*1. '''Chorioamnionitis'''<ref name="pmid17400872">{{cite journal| author=ACOG Committee on Practice Bulletins-Obstetrics| title=ACOG Practice Bulletin No. 80: premature rupture of membranes. Clinical management guidelines for obstetrician-gynecologists. | journal=Obstet Gynecol | year= 2007 | volume= 109 | issue= 4 | pages= 1007-19 | pmid=17400872 | doi=10.1097/01.AOG.0000263888.69178.1f | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17400872  }} </ref><ref name="pmid20569811">{{cite journal| author=Tita AT, Andrews WW| title=Diagnosis and management of clinical chorioamnionitis. | journal=Clin Perinatol | year= 2010 | volume= 37 | issue= 2 | pages= 339-54 | pmid=20569811 | doi=10.1016/j.clp.2010.02.003 | pmc=PMC3008318 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20569811  }} </ref>
*1. '''Chorioamnionitis'''<ref name="pmid17400872">{{cite journal| author=ACOG Committee on Practice Bulletins-Obstetrics| title=ACOG Practice Bulletin No. 80: premature rupture of membranes. Clinical management guidelines for obstetrician-gynecologists. | journal=Obstet Gynecol | year= 2007 | volume= 109 | issue= 4 | pages= 1007-19 | pmid=17400872 | doi=10.1097/01.AOG.0000263888.69178.1f | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17400872  }} </ref><ref name="pmid20569811">{{cite journal| author=Tita AT, Andrews WW| title=Diagnosis and management of clinical chorioamnionitis. | journal=Clin Perinatol | year= 2010 | volume= 37 | issue= 2 | pages= 339-54 | pmid=20569811 | doi=10.1016/j.clp.2010.02.003 | pmc=PMC3008318 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20569811  }} </ref><ref name="pmid33007269">{{cite journal |vauthors=Conde-Agudelo A, Romero R, Jung EJ, Garcia Sánchez ÁJ |title=Management of clinical chorioamnionitis: an evidence-based approach |journal=Am J Obstet Gynecol |volume=223 |issue=6 |pages=848–869 |date=December 2020 |pmid=33007269 |doi=10.1016/j.ajog.2020.09.044 |url=}}</ref>
:* Preferred regimen: [[Ampicillin]] 2 g IV q6h {{and}} ([[Gentamicin]] 1.5 mg/kg IV q8h {{or}} [[Gentamicin]] 5 mg/kg IV q24h) until delivery {{then}} ([[Ampicillin]] 2 g IV in a single dose {{or}} [[Gentamicin]] 5 mg/kg IV in a single dose) postpartum.
:*Preferred regimen: [[Ampicillin]] 2 g IV q6h {{and}} ([[Gentamicin]] 1.5- mg/kg IV q8h {{or}} [[Gentamicin]] 5 mg/kg IV q24h) until the delivery or [[Ampicillin-Sulbactam|Ampicillin/Sulbactam]] 3 g IV q6h until the delivery
:*Alternative regimen, penicillin-allergic: [[Clindamycin]] 900 mg IV q8h {{and}} ([[Gentamicin]] 1.5 mg/kg IV q8h {{or}} [[Gentamicin]] 5 mg/kg IV q24h) until delivery {{then}} ([[Clindamycin]] 900 mg IV in a single dose {{or}} [[Gentamicin]] 5 mg/kg IV in a single dose) postpartum.
:*Alternative regimen, penicillin-allergic: [[Clindamycin]] 900 mg IV q8h {{or}} [[Vancomycin]] 1 g IV q12h {{or}} [[Erythromycin]] (500 mg-1 g) IV q6h until the delivery
:* Note (1): For patients with cesarean section who are not penicillin-allergic, add [[Metronidazole]] 500 mg IV in a single dose only after clamping the umbilical cord.
:* Note (1): For patients with cesarean section, add [[Clindamycin]] 900 mg IV in a single dose only after clamping the umbilical cord ([[Metronidazole]] 500 mg IV is an alternative).
:* Note (2): For patients with cesarean section who are penicillin-allergic, [[Metronidazole]] should not be added post-partum.
:* Note (2): For patients with cesarean section who are penicillin-allergic, [[Metronidazole]] should be avoided post-partum.
:* Note (3): Chorioamnionitis is a contraindication to the administration of [[Corticosteroids]]. Women with intra-amniotic infection have traditionally been excluded from randomized trials of corticosteroid therapy.
*2. '''Supportive measures'''<ref name="pmid17400872">{{cite journal| author=ACOG Committee on Practice Bulletins-Obstetrics| title=ACOG Practice Bulletin No. 80: premature rupture of membranes. Clinical management guidelines for obstetrician-gynecologists. | journal=Obstet Gynecol | year= 2007 | volume= 109 | issue= 4 | pages= 1007-19 | pmid=17400872 | doi=10.1097/01.AOG.0000263888.69178.1f | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17400872  }} </ref><ref name="pmid33007269">{{cite journal |vauthors=Conde-Agudelo A, Romero R, Jung EJ, Garcia Sánchez ÁJ |title=Management of clinical chorioamnionitis: an evidence-based approach |journal=Am J Obstet Gynecol |volume=223 |issue=6 |pages=848–869 |date=December 2020 |pmid=33007269 |doi=10.1016/j.ajog.2020.09.044 |url=}}</ref>
*2. '''Supportive measures'''<ref name="pmid17400872">{{cite journal| author=ACOG Committee on Practice Bulletins-Obstetrics| title=ACOG Practice Bulletin No. 80: premature rupture of membranes. Clinical management guidelines for obstetrician-gynecologists. | journal=Obstet Gynecol | year= 2007 | volume= 109 | issue= 4 | pages= 1007-19 | pmid=17400872 | doi=10.1097/01.AOG.0000263888.69178.1f | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17400872  }} </ref>
:* Preferred regimen: [[Acetaminophen]] (325–650 mg) q(4-6)h PO (maximum, 4 g per day) as an antipyretic.
:* Preferred regimen: Antipyretics ([[Acetaminophen]])
:* Note (1): At least single dose of antenatal [[corticosteroids]] might decreased the neonatal mortality without causing an adverse outcomes (execarbation of infection or [[neonatal sepsis]]), therefore, it might be beneficial for women with clinical chorioamnionitis (gestational age between 24 0/7 and 33 6/7).
 
:* Note (2): While [[magnesium sulfate]] is a neuroprotective and decreases the risk of [[cerebral palsy]], it should be recommended for women with clinical chorioamnionitis (gestational age between 24 0/7 and 33 6/7).
==References==
==References==
{{reflist|2}}
{{reflist|2}}
Line 20: Line 20:
{{WS}}
{{WS}}
[[Category:Disease]]
[[Category:Disease]]
[[Category:Infectious disease]]
 
[[Category:Obstetrics]]
[[Category:Obstetrics]]
[[Category:Inflammations]]
[[Category:Inflammations]]
[[Category:Bacterial diseases]]
[[Category:Bacterial diseases]]
[[Category:NeedsEnglishReview]]

Latest revision as of 20:09, 12 June 2021

Chorioamnionitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Chorioamnionitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chorioamnionitis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chorioamnionitis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chorioamnionitis medical therapy

CDC on Chorioamnionitis medical therapy

Chorioamnionitis medical therapy in the news

Blogs on Chorioamnionitis medical therapy

Directions to Hospitals Treating Chorioamnionitis

Risk calculators and risk factors for Chorioamnionitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Adnan Ezici, M.D[2]

Overview

Antimicrobial therapy is indicated among patients with chorioamnionitis. The preferred regimen is a combination of ampicillin and gentamicin. Supportive therapy, such as antipyretics, may also be used.

Medical Therapy

Medical therapy for chorioamnionitis includes antimicrobial therapy and supportive therapy:

  • Preferred regimen: Ampicillin 2 g IV q6h AND (Gentamicin 1.5- mg/kg IV q8h OR Gentamicin 5 mg/kg IV q24h) until the delivery or Ampicillin/Sulbactam 3 g IV q6h until the delivery
  • Alternative regimen, penicillin-allergic: Clindamycin 900 mg IV q8h OR Vancomycin 1 g IV q12h OR Erythromycin (500 mg-1 g) IV q6h until the delivery
  • Note (1): For patients with cesarean section, add Clindamycin 900 mg IV in a single dose only after clamping the umbilical cord (Metronidazole 500 mg IV is an alternative).
  • Note (2): For patients with cesarean section who are penicillin-allergic, Metronidazole should be avoided post-partum.
  • Preferred regimen: Acetaminophen (325–650 mg) q(4-6)h PO (maximum, 4 g per day) as an antipyretic.
  • Note (1): At least single dose of antenatal corticosteroids might decreased the neonatal mortality without causing an adverse outcomes (execarbation of infection or neonatal sepsis), therefore, it might be beneficial for women with clinical chorioamnionitis (gestational age between 24 0/7 and 33 6/7).
  • Note (2): While magnesium sulfate is a neuroprotective and decreases the risk of cerebral palsy, it should be recommended for women with clinical chorioamnionitis (gestational age between 24 0/7 and 33 6/7).

References

  1. 1.0 1.1 ACOG Committee on Practice Bulletins-Obstetrics (2007). "ACOG Practice Bulletin No. 80: premature rupture of membranes. Clinical management guidelines for obstetrician-gynecologists". Obstet Gynecol. 109 (4): 1007–19. doi:10.1097/01.AOG.0000263888.69178.1f. PMID 17400872.
  2. Tita AT, Andrews WW (2010). "Diagnosis and management of clinical chorioamnionitis". Clin Perinatol. 37 (2): 339–54. doi:10.1016/j.clp.2010.02.003. PMC 3008318. PMID 20569811.
  3. 3.0 3.1 Conde-Agudelo A, Romero R, Jung EJ, Garcia Sánchez ÁJ (December 2020). "Management of clinical chorioamnionitis: an evidence-based approach". Am J Obstet Gynecol. 223 (6): 848–869. doi:10.1016/j.ajog.2020.09.044. PMID 33007269 Check |pmid= value (help).

Template:WH Template:WS